Female sex, n (%)
|
1008 (82.4)
|
1245 (82.7)
|
Age, years, n (%)
|
<50
|
470 (38.4)
|
580 (38.5)
|
≥50 to < 60
|
440 (35.9)
|
546 (36.3)
|
≥60 to < 70
|
247 (20.2)
|
300 (19.9)
|
≥70
|
67 (5.5)
|
80 (5.3)
|
Disease duration (years), n (%)
|
<2
|
261 (21.3)
|
323 (21.4)
|
≥2
|
963 (78.7)
|
1183 (78.6)
|
DAS28(CRP), mean (SD)
|
6.20 (0.83)
|
6.20 (0.85)
|
HAQ-DI, mean (SD)
|
1.65 (0.60)
|
1.65 (0.60)
|
CRP, mg/L, median (IQR)
|
15.0 (6.0–32.0)
|
15.0 (6.0–32.0)
|
Rheumatoid factor, IU/ml, median (IQR)
|
68.3 (18.9–201.1)
|
70.0 (19.4–200.0)
|
mTSS, median (IQR)
|
20.0 (5.5–54.7)
|
20.0 (6.0–55.0)
|
BMI, kg/m2, n (%)
|
<20
|
83 (6.8)
|
104 (6.9)
|
20–30
|
833 (68.1)
|
1024 (68.0)
|
>30
|
308 (25.2)
|
378 (25.1)
|
Glucocorticoid dose, mg/day, n (%)
|
0
|
518 (42.3)
|
637 (42.3)
|
>0–5
|
332 (27.1)
|
402 (26.7)
|
>5
|
374 (30.6)
|
467 (31.0)
|
Systemic MTX dose, mg/week, n (%)
|
≤15
|
1018 (83.2)
|
1261 (83.7)
|
>15
|
206 (16.8)
|
245 (16.3)
|
Medically treated comorbidities, n (%)a
| | |
Diabetes mellitus
|
47 (3.8)
|
53 (3.5)
|
COPD/asthma
|
34 (2.8)
|
38 (2.5)
|
Cardiac disorderb
|
15 (1.2)
|
17 (1.1)
|
Hypertensionc
|
387 (31.6)
|
465 (30.9)
|
Hyperlipidemia
|
55 (4.5)
|
66 (4.4)
|
Thyroid disorder
|
55 (4.5)
|
63 (4.2)
|
Osteoporosis
|
92 (7.5)
|
113 (7.5)
|
Depression
|
37 (3.0)
|
45 (3.0)
|